Innoviva (INVA) Accumulated Expenses (2010 - 2026)
Innoviva posted quarterly Accumulated Expenses of $3.9 million for Q1 2026, up 17.57% year-on-year from $3.3 million in Q1 2025, and up 6.29% on a QoQ basis from $3.7 million in Q4 2025.
Innoviva (INVA) has 17 years of Accumulated Expenses data on file, last reported at $3.9 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 17.57% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 17.57% YoY), and the FY2025 full-year result was $3.7 million, down 49.97% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $3.9 million, up from $3.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $38.0 million in Q2 2025 and bottomed at $231000.0 in Q3 2025.
- The 5-year median for Accumulated Expenses is $3.4 million (2023), against an average of $5.5 million.
- The widest annual swing landed in 2022, when Accumulated Expenses jumped 1056.3%; it then tumbled 90.84% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $8.0 million in 2022, then sank by 75.97% to $1.9 million in 2023, then soared by 282.57% to $7.4 million in 2024, then slumped by 49.97% to $3.7 million in 2025, then advanced by 6.29% to $3.9 million in 2026.
- The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $3.7 million (Q4 2025), and $231000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.92 Mn |
| Dec 31, 2025 | 3.69 Mn |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | 37.99 Mn |
| Mar 31, 2025 | 3.34 Mn |
| Dec 31, 2024 | 7.38 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 3.42 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 833,000.00 |
| Jun 30, 2023 | 3.42 Mn |
| Mar 31, 2023 | 833,000.00 |
| Dec 31, 2022 | 8.02 Mn |
| Sep 30, 2022 | 6.47 Mn |
| Jun 30, 2022 | 4.50 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 4.15 Mn |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 389,000.00 |
| Mar 31, 2021 | 1.67 Mn |
| Dec 31, 2020 | 490,000.00 |
| Sep 30, 2020 | 1.67 Mn |
| Jun 30, 2020 | 4.15 Mn |
| Mar 31, 2020 | 1.67 Mn |
| Dec 31, 2019 | 4.15 Mn |
| Sep 30, 2019 | 1.77 Mn |
| Jun 30, 2019 | 4.26 Mn |
| Mar 31, 2019 | 1.78 Mn |
| Dec 31, 2018 | 470,000.00 |
| Sep 30, 2018 | 1.55 Mn |
| Jun 30, 2018 | 5.12 Mn |
| Mar 31, 2018 | 2.55 Mn |
| Dec 31, 2017 | 1.72 Mn |
| Sep 30, 2017 | 1.65 Mn |
| Jun 30, 2017 | 7.10 Mn |
| Mar 31, 2017 | 998,000.00 |
| Dec 31, 2016 | 2.36 Mn |
| Sep 30, 2016 | 1.63 Mn |
| Jun 30, 2016 | 1.13 Mn |
| Mar 31, 2016 | 6.56 Mn |
| Dec 31, 2015 | 7.91 Mn |
| Sep 30, 2015 | 1.39 Mn |
| Jun 30, 2015 | 7.93 Mn |
| Mar 31, 2015 | 6.20 Mn |
| Dec 31, 2014 | 7.55 Mn |
| Sep 30, 2014 | 1.20 Mn |
| Jun 30, 2014 | 1.02 Mn |
| Mar 31, 2014 | 13.83 Mn |
| Dec 31, 2013 | 2.80 Mn |
| Sep 30, 2013 | 1.27 Mn |
| Jun 30, 2013 | 6.00 Mn |
| Mar 31, 2013 | 5.13 Mn |
| Dec 31, 2012 | 9.00 Mn |
| Sep 30, 2012 | 7.71 Mn |
| Jun 30, 2012 | 5.67 Mn |
| Mar 31, 2012 | 4.88 Mn |
| Dec 31, 2011 | 2.37 Mn |
| Sep 30, 2011 | 7.12 Mn |
| Jun 30, 2011 | 2.37 Mn |
| Dec 31, 2010 | 8.62 Mn |